Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Chubb
AstraZeneca
Daiichi Sankyo
Queensland Health
Cipla
Boehringer Ingelheim
Colorcon
Fish and Richardson

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,340,689

« Back to Dashboard

Which drugs does patent 6,340,689 protect, and when does it expire?

Patent 6,340,689 protects FACTIVE and is included in one NDA.

This patent has thirteen patent family members in twelve countries.
Summary for Patent: 6,340,689
Title: Methods of use of quinolone compounds against atypical upper respiratory pathogenic bacteria
Abstract:A method of treating an atypical upper respiratory pathogenic bacteria comprising administering a gemifloxacin compound is disclosed.
Inventor(s): Dubois; Jacques (Fleuramont, CA), St-Pierre; Claude (St-Elie d'Orford, CA)
Assignee: SmithKline Beecham Corporation (Philadelphia, PA)
Application Number:09/395,851
Patent Claim Types:
see list of patent claims
Use; Composition;

Drugs Protected by US Patent 6,340,689

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Lg Chem Ltd FACTIVE gemifloxacin mesylate TABLET;ORAL 021158-001 Apr 4, 2003 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial USE OF QUINOLONE COMPOUNDS AGAINST ATYPICAL UPPER RESPIRATORY PATHOGENIC BACTERIA ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 6,340,689

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,938,154 System, method and article of manufacture for a cryptographic key infrastructure for networked devices ➤ Try a Free Trial
6,331,550 Methods of use of quinolone compounds against anaerobic pathogenic bacteria ➤ Try a Free Trial
6,262,071 Methods of use of antimicrobial compounds against pathogenic amycoplasma bacteria ➤ Try a Free Trial
6,803,376 Method of use of quinolone compounds against pneumococcal and haemophilus bacteria ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,340,689

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal 1223935 ➤ Try a Free Trial
Japan 2003531101 ➤ Try a Free Trial
United Kingdom 9915597 ➤ Try a Free Trial
Spain 2299430 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Chinese Patent Office
Healthtrust
Citi
Cantor Fitzgerald
Harvard Business School
QuintilesIMS
Mallinckrodt
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.